Psychedelics, honestly — the evidence so far

Psychedelics are genuinely promising in supervised clinical trials for specific conditions — but that is not the same as safe recreational use, and the hype has run well ahead of approvals. Here is the honest state of the evidence.

What they are

Psilocybin (from "magic mushrooms"), LSD and — grouped with them though chemically different — MDMA are being studied as adjuncts to psychotherapy, given under supervision. The drug is not the treatment on its own: the therapy, preparation and integration around it do much of the work.

What’s actually promising

Real trials — but still emerging, mostly not yet approved.

• Psilocybin for treatment-resistant depression — Randomised trials show meaningful antidepressant effects from a single supervised dose with psychological support — but effects vary, and it is not an approved treatment yet. (emerging)
• MDMA-assisted therapy for PTSD — Phase-3 trials showed benefit for severe PTSD alongside therapy; the regulatory path is unfinished (the FDA asked for more data in 2024). Promising, not settled. (emerging)
• Set, setting and integration matter — The context — preparation, a safe supervised setting, and integration afterwards — is central to the trial results and to safety. Take that away and both benefit and safety change. (established)

The real risks

• Not for everyone — Contraindicated with a personal or family history of psychosis or bipolar disorder — psychedelics can trigger episodes. Trials screen carefully for this. (established)
• Challenging experiences — Intense anxiety, panic or destabilising "bad trips" can happen, particularly without proper set, setting and support. (established)
• MDMA-specific risks — At recreational doses/frequency there are neurotoxicity and overheating concerns, and dangerous interactions with SSRIs/MAOIs (serotonin syndrome). Street purity is unknown. (emerging)
• Legality and unregulated supply — These are mostly illegal outside trials, and street products carry unknown dose and purity — a major real-world risk. (note)

What’s oversold

• “Microdosing fixes everything” — Placebo-controlled studies of microdosing have mostly found little beyond placebo — a lot of the reported benefit is expectation. (hype)
• “One trip cures depression forever” — Trial effects are real but often need repeat dosing and therapy, and not everyone responds. It is not a one-shot cure. (hype)

What we still don’t know

• How durable the benefits are How long effects last, and how often re-dosing is needed, is still being worked out.
• Who benefits — and who is harmed Predicting responders, and the real-world risks outside carefully screened trials, remain open.
• Does microdosing do anything? The controlled evidence so far is largely unconvincing; this is genuinely unsettled.

Key terms

• Psilocybin The psychedelic compound in "magic mushrooms", studied for depression under supervision.
• MDMA An empathogenic drug studied (with therapy) for PTSD; not a classic psychedelic.
• Set and setting Your mindset and the environment — central to both the benefit and the safety of a psychedelic experience.
• Integration The therapeutic work of making sense of an experience afterwards; part of why supervised use differs from recreational.
• Microdosing Taking tiny, sub-perceptual doses regularly; controlled evidence for benefit is weak.